大剂量依托泊苷联合自体造血干细胞移植挽救性治疗进展期淋巴瘤的临床观察

doi:10.3969/j.issn.1007-3969.2014.10.006

中国癌症杂志 ›› 2014, Vol. 24 ›› Issue (10): 750-754.doi: 10.3969/j.issn.1007-3969.2014.10.006

大剂量依托泊苷联合自体造血干细胞移植挽救性治疗进展期淋巴瘤的临床观察

蔡宇,杨隽,姜杰玲,朱骏,王椿

上海交通大学附属第一人民医院血液科，上海 200080

出版日期:2014-10-30 发布日期:2014-11-12
通信作者: 王椿　E-mail:wangchun2@medmail.com.cn
作者简介:王椿，主任医师，教授，博士研究生导师，上海交通大学附属第一人民医院血液科主任，加拿大安大略肿瘤研究所骨髓移植中心博士后。中华医学会血液学分会委员兼秘书长，上海市医学会血液专科分会第九届委员会主任委员，上海市血液学研究所副所长、上海市器官移植临床医学中心副主任，中国抗癌协会血液肿瘤分会常委，上海市医学会感染与化疗专业委员会委员，兼任《中国感染与化疗杂志》常务编委，《中华内科杂志》、《中华血液学杂志》、《临床血液学杂志》、《白血病?淋巴瘤》等杂志编委。主要研究方向为运用自体或异基因造血干细胞移植治疗各类血液肿瘤，并且在移植嵌合状态监测上处于全国领先水平。擅长血液肿瘤疑难病例诊断与治疗及造血干细胞移植。在血液肿瘤发病机制及治疗对策上有独到见解。承担10多项国家和上海市科研课题，牵头上海及全国多中心临床实验5项。在Blood、Leukemia、Oncology、Experimental Hematology、《中华血液学杂志》、《中国实验血液学杂志》等国内外学术期刊共发表论文160余篇，其中SCI论文15篇。曾获省级科技进步三等奖和上海医学科技奖三等奖各1项。

High-dose etoposide in mobilization for 40 patients with refractory lymphoma

CAI Yu, YANG Juan, JIANG Jie-ling, ZHU Jun, WANG Chun

Department of Hematology, Shanghai Jiao Tong University Affiliated First People’s Hospital, Shanghai 201620

Published:2014-10-30 Online:2014-11-12
Contact: WANG Chun E-mail: wangchun2@medmail.com.cn

摘要/Abstract

摘要：

背景与目的：淋巴瘤复发是进展期淋巴瘤患者的主要死因，常规化疗疗效不佳。本研究旨在评估大剂量依托泊苷(VP16)联合自体造血干细胞移植治疗进展期淋巴瘤的疗效。方法：40例进展期淋巴瘤患者均接受大剂量VP16 10～15 mg/(kg·d)静脉滴注，持续2 d化疗，并在化疗后接受G-CSF 5～10 μg/kg皮下注射，至白细胞计数>4×109/L，采集患者干细胞并冻存于-80 ℃深低温冰箱中；40例患者均接受自体造血干细胞移植。结果：VP16治疗后中位随访时间39 d(17～172 d)，40例患者中12(30%)例对大剂量VP16无反应，28(70%)例有反应。自体干细胞移植后，中位随访28个月(4～66 d)。40例患者中，16(40%)例达到完全缓解，其中对VP16有反应的28例患者，15(53.6%)例达到完全缓解，4(14.3%)例部分缓解，9(32.1%)例死于疾病进展，对VP16无反应的12例患者，仅1(8.3%)例达到完全缓解。1(8.3%)例部分缓解，10(83.4%)例死于疾病进展。对VP16有反应的患者1年的无事件生存率(event-free survival，EFS)为56.7%，总体生存率(overall survival，OS)为69.0%，2年EFS为52.0%，OS为63.0%。无反应的患者1年EFS为16.7%，OS为25.0%，2组数据相比，差异有统计学意义(P<0.01)。结论：大剂量VP16联合自体造血干细胞移植能使对大剂量VP16有反应的患者带来较高的EFS和OS，可作为难治性淋巴瘤患者挽救性治疗的选择之一。

关键词: 大剂量VP16, 进展期淋巴瘤, 自体造血干细胞移植

Abstract:

Background and purpose: The patients with aggressive lymphoma who have a poor prognosis and unlikely to be cured with conventional chemotherapy. This study was aimed to evaluate the effect of high-dose etoposide in mobilization followed auto-SCT in treating refractory lymphoma. Methods: 40 patients [median age 33 (13-61) years] with refractory non-Hodgkin’s lymphoma (NHL, n=32) or Hodgkin’s lymphoma (HD, n=8) received high-dose etoposide [VP16 10-15 mg/(kg·d)×2 d] in mobilization in our center. Remission status prior to mobilization was PD (n=40). The use of such granulocyte colony-stimulating factor [G-CSF, 5-10 μg/(kg·d)] mobilized peripheral blood stem cells (PBSC) after high-dose etoposide until the end of leukapheresis. Peripheral blood stem cell was collected and frozen in -80℃ refrigerator. All these patients received auto peripheral blood stem cell transplantation (auto-PBSCT). Conditioning regimen was BEAM (n=19, 47.5%) or CBV (n=21, 52.5%). Results: Twenty-eight patients (70%) were assessable for response after high-dose etoposide at a median pretreatment time of 39 days (range 17-172 days), 12 patients (30%) had no response. Median follow-up of 28 (4-66) months, 16 patients (40%) reached CR after auto-PBSCT. Fifteen of the 28 patients (53.6%) who had response to high-dose etoposide reached CR, 4 patients (14.3%) reached PR, 9 patients (32.1%) succumb to progression of disease. One of the 12 patients (8.3%) who had no response to high-dose etoposide reached CR, 1 patients (8.3%) reached PR, 10 patients (83.4%) succumb to progression of disease. The estimated 1-year OS and EFS were 69% and 56.7% respectively, 2-years OS and EFS were 63% and 52% respectively. The prognosis of the patients who had no response to etoposide was poor. The estimated 1-year OS and EFS were 25% and 16.7% respectively. Two group of comparison differences have statistics significance (P<0.01). Conclusion: High-dose etoposide could be used in refractory lymphoma as rescue therapy in mobilization. It can increase the EFS and OS of patients who had response. The hematopoietic stem cells collection and hematopoietic reconstitution are not affected by etoposide.

Key words: High-dose etoposide, Refractory lymphoma, Autologous stem cell transplantation

蔡宇,杨隽,姜杰玲,朱骏,王椿. 大剂量依托泊苷联合自体造血干细胞移植挽救性治疗进展期淋巴瘤的临床观察[J]. 中国癌症杂志, 2014, 24(10): 750-754.

CAI Yu, YANG Juan, JIANG Jie-ling, ZHU Jun, WANG Chun. High-dose etoposide in mobilization for 40 patients with refractory lymphoma[J]. China Oncology, 2014, 24(10): 750-754.

大剂量依托泊苷联合自体造血干细胞移植挽救性治疗进展期淋巴瘤的临床观察

High-dose etoposide in mobilization for 40 patients with refractory lymphoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价